MedTrace Logo

Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer

NCT06355050 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-09-08

No results posted yet for this study

Summary

In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.

Conditions

Sponsors & Collaborators

  • University Hospital Schleswig-Holstein

    collaborator OTHER

  • Klinikum Stuttgart

    collaborator OTHER

  • University Medical Center Göttingen

    collaborator UNKNOWN

  • Kantonsspital Aarau

    collaborator OTHER

  • Hirslanden Stephanshorn

    collaborator UNKNOWN

  • Universitätsklinik Würzburg

    collaborator UNKNOWN

  • Radiologische Allianz Hamburg

    collaborator UNKNOWN

  • Jena University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2027-09-30
Completion
2032-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06355050 on ClinicalTrials.gov